Overall Status

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

phase 3 (1)

Sponsor

Daxor Corporation (1)

Goldfinch Bio, Inc. (1)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Collaborator

Intervention

gfb-887 (1)

oral dexamethasone (1)

placebo (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

NIH (1)

Study Type

Interventional (2)

Observational (1)

nephrosis

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental Trial in United States (GFB-887, Placebo)

Recruiting

Kidney Diseases
+10 more

GFB-887
Placebo

Birmingham, Alabama
+75 more

Mar 29, 2022

Utilizing a Modification of the BVA 100 Blood Volume Analyzer

Completed

Hypoalbuminemia
+4 more

(no location specified)

Mar 1, 2012

Nephrosis, Focal Lipoid Glomerulosclerosis Trial run by the NIDDK (Oral dexamethasone)

Completed

Nephrosis
Focal Lipoid Glomerulosclerosis

Oral dexamethasone

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Sep 20, 2011